{"title":"更正“现实世界从业者对先前治疗过的多发性骨髓瘤患者的cartitute -4结果的看法”","authors":"","doi":"10.1002/jha2.70050","DOIUrl":null,"url":null,"abstract":"<p>Balanean A, Baird S, Dulka B, Jennings-Zhang L, Bone RN, Jeune-Smith Y, et al. Real-world practitioner perceptions of CARTITUDE-4 results for patients with previously treated multiple myeloma. eJHaem. 2024;5:1154-64. https://doi.org/10.1002/jha2.1047</p><p>In Figure 3 the “After” percentages for two response options were inadvertently transposed in the figure, creating an inconsistency with the description provided in the text.</p><p>Specifically:</p><p>The “After” result for the response option “I favor CAR T-cell therapy in earlier lines (e.g., 2L or 3L settings)” should be 55% (not 31%).</p><p>The “After” result for the response option “I want real-world and long-term outcomes data on CAR T-cell therapy in any line” should be 31% (not 55%).</p><p>We apologize for this error.</p>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.70050","citationCount":"0","resultStr":"{\"title\":\"Correction to “Real-World Practitioner Perceptions of CARTITUDE-4 Results for Patients With Previously Treated Multiple Myeloma”\",\"authors\":\"\",\"doi\":\"10.1002/jha2.70050\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Balanean A, Baird S, Dulka B, Jennings-Zhang L, Bone RN, Jeune-Smith Y, et al. Real-world practitioner perceptions of CARTITUDE-4 results for patients with previously treated multiple myeloma. eJHaem. 2024;5:1154-64. https://doi.org/10.1002/jha2.1047</p><p>In Figure 3 the “After” percentages for two response options were inadvertently transposed in the figure, creating an inconsistency with the description provided in the text.</p><p>Specifically:</p><p>The “After” result for the response option “I favor CAR T-cell therapy in earlier lines (e.g., 2L or 3L settings)” should be 55% (not 31%).</p><p>The “After” result for the response option “I want real-world and long-term outcomes data on CAR T-cell therapy in any line” should be 31% (not 55%).</p><p>We apologize for this error.</p>\",\"PeriodicalId\":72883,\"journal\":{\"name\":\"EJHaem\",\"volume\":\"6 3\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-05-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.70050\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EJHaem\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jha2.70050\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJHaem","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jha2.70050","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
Balanean A, Baird S, Dulka B, Jennings-Zhang L, Bone RN, Jeune-Smith Y，等。现实世界从业者对先前治疗过的多发性骨髓瘤患者的CARTITUDE-4结果的看法。eJHaem。2024; 5:1154 - 64。https://doi.org/10.1002/jha2.1047In图3两个回答选项的“After”百分比在图中被无意地调换了位置，造成了与文本中提供的描述不一致。具体来说：对于应答选项“我倾向于早期的CAR - t细胞治疗（例如，2L或3L设置）”，“之后”的结果应该是55%（而不是31%）。应答选项“我想要任何类型的CAR -t细胞治疗的真实世界和长期结果数据”的“之后”结果应该是31%（而不是55%）。我们为这个错误道歉。
Correction to “Real-World Practitioner Perceptions of CARTITUDE-4 Results for Patients With Previously Treated Multiple Myeloma”
Balanean A, Baird S, Dulka B, Jennings-Zhang L, Bone RN, Jeune-Smith Y, et al. Real-world practitioner perceptions of CARTITUDE-4 results for patients with previously treated multiple myeloma. eJHaem. 2024;5:1154-64. https://doi.org/10.1002/jha2.1047
In Figure 3 the “After” percentages for two response options were inadvertently transposed in the figure, creating an inconsistency with the description provided in the text.
Specifically:
The “After” result for the response option “I favor CAR T-cell therapy in earlier lines (e.g., 2L or 3L settings)” should be 55% (not 31%).
The “After” result for the response option “I want real-world and long-term outcomes data on CAR T-cell therapy in any line” should be 31% (not 55%).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
